Comparative Pharmacology
Head-to-head clinical analysis: DESOXYN versus DYANAVEL XR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOXYN versus DYANAVEL XR 5.
DESOXYN vs DYANAVEL XR 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desoxyn (methamphetamine) is a sympathomimetic amine that promotes release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals, blocks their reuptake, and inhibits monoamine oxidase (MAO) activity. It produces CNS stimulation and peripheral alpha- and beta-adrenergic effects.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
Adults: 5-60 mg/day orally in divided doses, typically starting at 5 mg twice daily; maximum 60 mg/day.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 9–14 hours (mean 12 hours) in adults; prolonged in alkaline urine (up to 25–30 hours). Clinically, twice-daily dosing maintains steady state after 2–3 days.
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
Renal: ~90% as unchanged drug and metabolites (primarily 4-hydroxyephedrine and 4-hydroxynorephedrine) within 48 hours; urinary pH-dependent: acidic urine increases elimination. Biliary/fecal: minor.
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant